Clinical trials in first candidate will start in 2008.

Quantum Genomics (QGC), Inserm, CNRS, and the University Paris Descartes are collaborating to develop drugs for hypertension and related cardiovascular diseases.

The first compound, QGC001, to be pursued will be a candidate from discoveries by teams led by Catherine Llorens-Cortes, director of Inserm Unit 691, and Bernard P. Roques at Inserm Unit 640, based in the University of Paris Descartes. QGC expects to start a clinical trial in 2008.

Under the terms of the contract, QGC acquires rights to exploit three patents and associated know-how. Inserm and CNRS will work on the physiopathology, chemistry, and understanding of the compound’s mechanism of action, whereas QGC will handle preclinical and clinical development and regulatory aspects.

Previous articleReal Time Quantitative PCR (RT-qPCR) in a Clinical Reference Laboratory
Next articleGene Logic to Reposition Lundbeck Candidates